Social media

Are you going to the EHRA Congress? If so come along to Lennaert Hoek’s poster presentation on the validity and reliability of a smartwatch single-lead ECG for monitoring QT interval prolongation during an intervention...

Selecting the right pediatric HRQoL instrument is no longer optional. It’s a regulatory expectation. Our latest blog breaks down a six criterion framework to guide sponsors in making defensible, patient focused choices, ...

Heterogeneity influences the credibility of any meta analysis. Our whitepaper explains how clinical, methodological and statistical differences affect evidence synthesis and when fixed effect or random effects models a...

Heterogeneity influences the credibility of any meta analysis. Our whitepaper explains how clinical, methodological and statistical differences affect evidence synthesis and when fixed effect or random effects models a...

If 2025 proved anything for HTA developers, it’s that PICO complexity is real. The first operational JCAs confirmed that navigating diverse standards of care across EU Member States creates continued uncertainty for spon...

If 2025 proved anything for HTA developers, it’s that PICO complexity is real. The first operational JCAs confirmed that navigating diverse standards of care across EU Member States creates continued uncertainty for spon...

Central monitoring and on-site monitoring are often positioned as competing approaches. In reality, both play a critical role in how modern trials are delivered. As studies become more complex, the focus is shifting tow...

Central monitoring and on-site monitoring are often positioned as competing approaches. In reality, both play a critical role in how modern trials are delivered. As studies become more complex, the focus is shifting tow...

Attending the GLP-1-Based Therapeutics Summit? Meet the ICON team to learn about our proven success designing and executing early phase studies, supported by a robust database of overweight/obese healthy volunteers and...

On 15 April at 12:00 pm, join ICON’s Alan Baldridge at the GLP-1-Based Therapeutics Summit where he will be speaking on “Is there anything GLP‑1s can’t do? Unlocking the next generation of metabolic treatments.” He’ll c...

Latest issue out now. Do you struggle to keep on top of regulatory changes affecting the world of medicine and medical device clinical trials? Join thousands of subscribers who have discovered the convenience of our ...

ICON’s Patient Centred Outcomes team advanced key research in 2025, with over 45 highly experienced specialists supporting programmes across major therapy areas. With twelve peer‑reviewed papers, two educational events...